{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-066545","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.278017+00:00","generated_at":"2026-06-01T07:19:27.124046+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus closes $75M sale of royalty and milestone rights to Ligand","bullets":["Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.","Sold 31.875% of development/regulatory/commercial milestone payments under five license agreements with BMS, Incyte, Merck, UroGen, Gilead.","Sold 18.75% of royalties from those agreements and 2.625% synthetic royalty on botensilimab/balstilimab net sales.","Transaction closed May 29, 2024; proceeds net of certain expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-066545","json":"https://secwatch.observer/filing/0000950170-24-066545.json","markdown":"https://secwatch.observer/filing/0000950170-24-066545.md","text":"https://secwatch.observer/filing/0000950170-24-066545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/0000950170-24-066545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/agen-20240529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:19:27.124046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab1a99ec22b7f1e26bcacd971e5be030f828f408","claim":"AGENUS INC completed a disposition involving Ligand Pharmaceuticals Incorporated for $75 million (closed 2024-05-29).","evidence_excerpt":"On May 29, 2024, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on May 30, 2024, Agenus received consideration of $75 million, less certain reimbursable expenses upon the completion of the sale to Ligand of the following assets: (i) 31.875% of the development, regulatory and commercial milestone","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024066545/0000950170-24-066545-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Ligand Pharmaceuticals Incorporated"},{"label":"Consideration","value":"$75 million"},{"label":"Closing","value":"2024-05-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}